QuantumScape reports Q4 EPS (25c), consensus (21c)

"While specific customer testing protocols and results can’t be disclosed, we can report that generally, most cells have performed well on initial testing, including fast charge and early-cycle capacity retention; however, we must continue to improve cell reliability as we move from prototype to product," the company said. "This is a key focus area for 2023, and we expect that as we make progress on the quality and consistency of our materials and processes, reliability will continue its upward trajectory. We have identified specific opportunities to deliver such improvements and expect to incorporate these into our baseline processes over the course of the year."